Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash & Equivalents (2021 - 2025)

Lucid Diagnostics' Cash & Equivalents history spans 5 years, with the latest figure at $34.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 55.2% year-over-year to $34.7 million; the TTM value through Dec 2025 reached $34.7 million, up 55.2%, while the annual FY2025 figure was $34.7 million, 55.2% up from the prior year.
  • Cash & Equivalents reached $34.7 million in Q4 2025 per LUCD's latest filing, down from $47.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $53.7 million in Q4 2021 to a low of $21336.0 in Q3 2021.
  • Average Cash & Equivalents over 5 years is $26.3 million, with a median of $25.1 million recorded in 2024.
  • The largest YoY upside for Cash & Equivalents was 126137.35% in 2022 against a maximum downside of 58.11% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $53.7 million in 2021, then tumbled by 58.11% to $22.5 million in 2022, then decreased by 15.92% to $18.9 million in 2023, then rose by 18.32% to $22.4 million in 2024, then surged by 55.2% to $34.7 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Cash & Equivalents are $34.7 million (Q4 2025), $47.3 million (Q3 2025), and $31.1 million (Q2 2025).